| Trial ID: | L3534 |
| Source ID: | NCT00366301
|
| Associated Drug: |
Insulin Glargine Injection
|
| Title: |
The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00366301/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Insulin glargine injection|DRUG: metformin|DRUG: Placebo pill
|
| Outcome Measures: |
Primary: Percentage Reduction in C-reactive Protein (CRP), 14 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Brigham and Women's Hospital | Collaborators: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
500
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-08
|
| Completion Date: |
2009-04
|
| Results First Posted: |
2010-11-25
|
| Last Update Posted: |
2010-11-25
|
| Locations: |
Brigham and Women's Hospital, Boston, Massachusetts, 02215, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00366301
|
